Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack A Brown

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
British Journal of Clinical Pharmacology|November 13, 2021
A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitorJack A Brown, Joanne Bal, Monica Simeoni, et al.
Journal of Medicinal Chemistry|January 12, 2016
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral DosesEmmanuel H Demont, James M Bailey, Rino A Bit, et al.
Epigenetics & Chromatin|March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learnedStephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Journal of Medicinal Chemistry|January 16, 2016
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one DerivativesSusan M Westaway, Alex G S Preston, Michael D Barker, et al.
Journal of Medicinal Chemistry|January 16, 2016
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate DerivativesSusan M Westaway, Alex G S Preston, Michael D Barker, et al.
Journal of Medicinal Chemistry|January 7, 2020
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment ScreeningChristopher R Wellaway, Dominique Amans, Paul Bamborough, et al.
Journal of Medicinal Chemistry|June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
British Journal of Clinical Pharmacology|November 13, 2021
A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitorJack A Brown, Joanne Bal, Monica Simeoni, et al.
Journal of Medicinal Chemistry|January 12, 2016
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral DosesEmmanuel H Demont, James M Bailey, Rino A Bit, et al.
Epigenetics & Chromatin|March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learnedStephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Journal of Medicinal Chemistry|January 16, 2016
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one DerivativesSusan M Westaway, Alex G S Preston, Michael D Barker, et al.
Journal of Medicinal Chemistry|January 16, 2016
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate DerivativesSusan M Westaway, Alex G S Preston, Michael D Barker, et al.
Journal of Medicinal Chemistry|January 7, 2020
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment ScreeningChristopher R Wellaway, Dominique Amans, Paul Bamborough, et al.
Journal of Medicinal Chemistry|June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Pageof 2